Ofla OZ Tablet is a combination antibiotic formulation containing Ofloxacin 200 mg and Ornidazole 500 mg, indicated for the treatment of mixed bacterial and protozoal infections. Ofloxacin, a fluoroquinolone antibiotic, exerts bactericidal action by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial DNA replication and transcription. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by disrupting DNA synthesis and causing cell death. This synergistic combination is particularly useful in managing complicated infections such as gastrointestinal infections, genitourinary tract infections, respiratory tract infections, and certain sexually transmitted infections where mixed aerobic and anaerobic pathogens are suspected. Ofla OZ Tablet is prescribed to ensure broad-spectrum antimicrobial coverage, reducing the risk of resistance development and improving therapeutic outcomes. It is essential to use this medication under medical supervision, adhering to the prescribed dosage and duration to prevent adverse effects and resistance. Common side effects may include gastrointestinal disturbances, headache, dizziness, and hypersensitivity reactions. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, as well as those with hepatic or renal impairment. Ofla OZ Tablet should be avoided during pregnancy and lactation unless deemed necessary by a healthcare professional.